← Beijing Sun Novo Pharmaceutical Research overview

Beijing Sun Novo Pharmaceutical Research vs Zhejiang Huahai Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Beijing Sun Novo Pharmaceutical Research Co Ltd (688621.CG)

Q3 202614 Jul – 31 Aug 2026

▲2▼1

Sunshine Nuohe Swings to Loss as Pipeline Advances

H1 2026 swing to net loss Sunshine Nuohe reported a first-half 2026 net loss of 24.4 million yuan, versus a 130 million yuan profit a year earlier, as revenue fell 27.81% to 426 million yuan. The absence of large out-licensing deals and pressure on pharma revenue drove the swing, weighing on the stock.
The loss is the core financial result that directly pressures the share price.
STC009 injection wins clinical trial approval A subsidiary received regulatory clearance to begin human testing of STC009, a Class 1 innovative drug for secondary hyperparathyroidism. This milestone advances the pipeline and signals progress in the company's peptide drug platform, supporting future value.
Clinical approval is a concrete pipeline win that can lift investor sentiment.
STC007 out-licensed and pipeline builds The interim report highlighted that self-developed STC007 for pruritus completed an out-licensing deal, STC008 for cancer cachexia is in trials, and multiple peptide, small nucleic acid, and CAR-T programs entered clinical stage. R&D spending rose to 20.54% of revenue, supporting long-term growth.
Pipeline progress and out-licensing show the innovation strategy is delivering, a positive counterweight to the loss.
Controlling shareholder sells 5% stake Controlling shareholder Li Qian transferred 5% of the company to a fund at 41.56 yuan per share for 233 million yuan. Control is unchanged and the buyer locked up for 12 months, but the sale adds supply and may raise governance or confidence questions.
The stake sale is a capital event that can affect supply and sentiment, though its impact is ambiguous.

August 202614 Jul – 31 Aug 2026

▲2▼1

Sunshine Nuohe Swings to Loss as Pipeline Advances

H1 2026 swing to net loss Sunshine Nuohe reported a first-half 2026 net loss of 24.4 million yuan, versus a 130 million yuan profit a year earlier, as revenue fell 27.81% to 426 million yuan. The absence of large out-licensing deals and pressure on pharma revenue drove the swing, weighing on the stock.
The loss is the core financial result that directly pressures the share price.
STC009 injection wins clinical trial approval A subsidiary received regulatory clearance to begin human testing of STC009, a Class 1 innovative drug for secondary hyperparathyroidism. This milestone advances the pipeline and signals progress in the company's peptide drug platform, supporting future value.
Clinical approval is a concrete pipeline win that can lift investor sentiment.
STC007 out-licensed and pipeline builds The interim report highlighted that self-developed STC007 for pruritus completed an out-licensing deal, STC008 for cancer cachexia is in trials, and multiple peptide, small nucleic acid, and CAR-T programs entered clinical stage. R&D spending rose to 20.54% of revenue, supporting long-term growth.
Pipeline progress and out-licensing show the innovation strategy is delivering, a positive counterweight to the loss.
Controlling shareholder sells 5% stake Controlling shareholder Li Qian transferred 5% of the company to a fund at 41.56 yuan per share for 233 million yuan. Control is unchanged and the buyer locked up for 12 months, but the sale adds supply and may raise governance or confidence questions.
The stake sale is a capital event that can affect supply and sentiment, though its impact is ambiguous.

Latest14 Jul – 31 Aug 2026

▲2▼1

Sunshine Nuohe Swings to Loss as Pipeline Advances

H1 2026 swing to net loss Sunshine Nuohe reported a first-half 2026 net loss of 24.4 million yuan, versus a 130 million yuan profit a year earlier, as revenue fell 27.81% to 426 million yuan. The absence of large out-licensing deals and pressure on pharma revenue drove the swing, weighing on the stock.
The loss is the core financial result that directly pressures the share price.
STC009 injection wins clinical trial approval A subsidiary received regulatory clearance to begin human testing of STC009, a Class 1 innovative drug for secondary hyperparathyroidism. This milestone advances the pipeline and signals progress in the company's peptide drug platform, supporting future value.
Clinical approval is a concrete pipeline win that can lift investor sentiment.
STC007 out-licensed and pipeline builds The interim report highlighted that self-developed STC007 for pruritus completed an out-licensing deal, STC008 for cancer cachexia is in trials, and multiple peptide, small nucleic acid, and CAR-T programs entered clinical stage. R&D spending rose to 20.54% of revenue, supporting long-term growth.
Pipeline progress and out-licensing show the innovation strategy is delivering, a positive counterweight to the loss.
Controlling shareholder sells 5% stake Controlling shareholder Li Qian transferred 5% of the company to a fund at 41.56 yuan per share for 233 million yuan. Control is unchanged and the buyer locked up for 12 months, but the sale adds supply and may raise governance or confidence questions.
The stake sale is a capital event that can affect supply and sentiment, though its impact is ambiguous.

Zhejiang Huahai Pharmaceutical Co Ltd (600521.CG)

Q3 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

August 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

Latest24 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.